|
American Association for Cancer Research Annual Meeting 2026
Friday, April 17 – Wednesday, April 22
San Diego, California
Learn about the National Cancer Institute’s (NCI), Division of Cancer Prevention (DCP) presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting. Presentation topics include funding opportunities in cancer diagnosis, leveraging NCI-supported cancer epidemiology cohorts to advance cancer prevention and control, biospecimen resources and cancer biology; opportunities to support early career cancer researchers; modernizing clinical trial communication with AI; and more.
DCP Participation at AACR
NCI-NIH selected sessions, leadership and staff presentations
|
DCP Early Career Scientist Spotlight Research Seminar Series
Join DCP for two virtual talks from early career scientists who are advancing research in cancer prevention, detection, and symptom science.
|
Thursday, May 7
11:00 a.m.-Noon ET
Advance registration required
David Cordas dos Santos, M.D., instructor, Dana-Farber Cancer Institute and Harvard Medical School, will give a talk on “Adding the Spatial Dimension: Insights From Spatial Omics in Hematologic Malignancies,” and Sebnem Ece Eksi, Ph.D., assistant professor, Oregon Health & Science University, will give a talk on "Spatiotemporal Mapping of Tumor Innervation to Predict Aggressive Prostate Cancer at Early Stages.”
|
|
 |
|
Tuesday, May 26
11:00 a.m.-Noon ET
Advance registration required
Jessica E. S. Shay, M.D., Ph.D., assistant professor, University of Utah, will give a talk on “Nutrient Stress to Neoplasia: Uncovering Metabolic Drivers of Hepatocellular Transformation,” and Samuel Yates, M.D., M.Sc., fellow, University of Chicago, will give a talk on “Fitness Assessment and Optimization in Older Adults with AML: A Focus on Sarcopenia.”
Learn more about the Early Career Scientist Research Seminar Series.
|
|
 |
Reversing Carcinogenesis for Cancer Prevention Virtual Workshop
Monday, June 1 – Tuesday, June 2
11:00 a.m.-4:30 p.m. ET
Advance registration required
DCP and the Division of Cancer Biology at NCI are co-sponsoring a free virtual workshop to identify knowledge gaps and develop strategic research plans focused on reversing carcinogenesis for cancer prevention and interception. Experts will explore key topics including the microenvironment, microbiome, and systems biology to advance strategies for carcinogenesis reversion.
For more information, access the event page.
|
The Cancer Prevention Research Conference 2026
Wednesday, June 3 – Friday, June 5
Atlanta, Georgia
Advance registration required
Join researchers from around the world at the Cancer Prevention Research Conference to discuss big questions facing cancer prevention with the brightest minds in prevention research. Phil Castle, Ph.D., M.P.H., director, DCP, will lead a fireside chat on Friday, June 5 at 2:10 p.m. ET.
Access the meeting agenda.
|
|
|
Chronic Inflammation Leaves Long-Lasting Impression on Gut Stem Cells, Increasing Colorectal Cancer Risk
|
In a new preclinical study, funded in part by the National Institutes of Health (NIH), researchers have uncovered a molecular mechanism that could explain how chronic gut inflammation may increase the risk of colorectal cancer. This study is part of the Cancer Grand Challenges team PROSPECT which is partially supported by NCI grants 1OT2CA297577 and 3OT2CA297577.
Read the NIH Press Release.
|
|
 |
|
|
RASH3D19 Mediates RAS Activation Through a Positive Feedback Loop in KRAS-Mutant Cancer
|
In a preclinical study published in Nature Cell Biology, NCI-funded researchers found that a molecule called RASH3D19 helps some cancers resist drugs that target KRAS, a gene that helps control cell grown and is often altered in cancer. The study suggests that blocking RASH3D19 could be a new way to improve treatment for cancers driven by KRAS mutations. This work was supported in part by the NCI Pancreatic Cancer Detection Consortium (PCDC) U01 funding.
Read the paper and the accompanying Nature Portfolio article.
|
|
 |
Homologous Recombination Repair Germline Variants and Subsequent Neoplasm Risk Among Childhood Cancer Survivors
|
An NCI-funded study found that childhood cancer survivors with inherited variants in DNA repair genes were 2.5 times more likely to develop another cancer — particularly thyroid or breast cancer — outside their original radiation treatment field. The findings support considering genetic testing as part of long-term follow-up care for childhood cancer survivors. Shahriar Zamani, Ph.D., NCI Cancer Prevention Fellow, co-authored the paper.
Read the paper.
|
|
 |
|
|
|
|
|
